Not if, but when and how. That's the conclusion most biopharmaceutical executives have today when it comes to developing a global strategy — increasingly focused on Asia. China will likely be the second-largest pharmaceutical market by 2020, surpassing Japan. Surrounding countries, such as Taiwan and South Korea already have powerful biotechnology and biosimilars sub-sectors well established. To succeed in today's global economy an Asia strategy is not optional.
In response to a rapidly increasing demand for more news from this region, BioWorld Asia debuts to provide biopharma executives with a trusted, steady stream of content from this critical part of the world, providing information and data to help shape short- and long-term business decisions.
BioWorld Asia is a weekly publication that is modeled after BioWorld Today, which provides focused updates on business, financial, clinical, scientific and regulatory developments affecting the biopharma industry.
Read beyond the obvious, with timely, in-depth coverage of Asia's biopharma sector, with trademark BioWorld analysis and perspective on licensing deals, M&A and financings
Untangle the regulatory knots with articles that clarify the process in China and other key markets
Enhance partnering opportunities by getting to know the people and companies via BioWorld's signature BioPeople and NewCo News features
Recognize deal trends and various financing options available to fund R&D
Understand how the recent corruption scandals are affecting drug regulation in China and what that means for the biopharma industry
Comprehend the myriad regulatory paths for biosimilars
Assuage intellectual property concerns with articles that highlight this hot-button topic
Learn about joint regulatory schemes, such as one developing between Australia and New Zealand
Stay on top of clinical news with incremental updates on drugs in the pipeline from early to late-stage through regulatory reviews, approvals or denials